Biocon Biologics Acquired Viatris For Over $3 Billion
Global biopharmaceutical company Biocon Biologics Ltd. announced, on Tuesday, the completion of the acquisition of Viatris, a pharmaceutical company, for almost $3 billion. According to the reports, the million-dollar acquisition was completed in two parts; equity and cash. Biocon Biologics paid upfront cash of $2 billion and issued Compulsorily Convertible Preference Shares (CCPS) worth $1…
Vipin